Medidata Solutions
today announced that
Galderma
has standardized on the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform.
Based in Lausanne, Switzerland with a presence in 65 countries, Galderma operates one of the world’s largest R&D facilities dedicated exclusively to developing treatments for dermatological conditions. These state-of-the-art laboratories, located in Sophia Antipolis, France, are complemented by development centers in Princeton, New Jersey and Tokyo, Japan. With an ongoing need to conduct an expanding number of global clinical trials, Galderma’s data management team conducted an extensive, six-month evaluation of three vendors before selecting Medidata Solutions.
“Medidata’s track record executing global trials across all trial phases, coupled with their professionalism, proactivity and responsiveness, was critical to our rollout of the Rave solution,” said Francis Gon, head of Global Data Management at Galderma. “Medidata’s training and eLearning tools also made it easy for us to take the solution in-house and begin to independently build and execute studies in any phase and in multiple languages.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.